Jim Cramer says Roche's $8.3 billion bid for U.S. biotech firm InterMune means big pharma is thinking big. Cramer says there are so many biotech companies out there losing money as InterMune was, while at the same time companies like Roche, Merck, Pfizer and Glaxo need to make acquisitions for growth. He says the game plan for these companies is to find a biotech that may have a drug breakthrough and is about to get FDA approval. In this case, Roche, the Swiss drugmaker, is hoping to cash in on the pending U.S. approval of California-based InterMune's new drug that treats a deadly lung disease. Roche says it will continue to focus on targeted acquisitions.

More from Video

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

KPMG Chair & CEO: There's No One-Size-Fits-All Approach to Diversity

KPMG Chair & CEO: There's No One-Size-Fits-All Approach to Diversity

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer: Intuit Had a Fantastic Quarter